Condensed a compact overview of the section

Fenbendazole is a benzimidazole-class anthelmintic widely used in animals. In the United States it is marketed and approved for veterinary use; there is no routine FDA approval for treating humans. Veterinary products commonly come in formulations and dose units labeled near 222 mg or 444 mg per unit depending on brand and presentation.

Readers seeking human treatment options should consult a licensed healthcare professional. Inspect the data sections on different substitutes, costing options, and regulation for further context and links to related topics on this page.

What fenbendazole stands for

Fenbendazole acts by interfering with parasite microtubules and energy metabolism, which reduces survival of many helminths and some protozoa. It belongs to the benzimidazole family of antiparasitic agents used in veterinary medicine.

Laboratory and animal studies have described cellular effects that led to interest in possible anticancer properties, but evidence in humans is limited and not conclusive. These experimental findings do not equal approved or proven cancer therapy.

Approval: veterinary use versus human use

In the United States, fenbendazole is approved only for animals. Indicia deemed approved include control of various gastrointestinal worms in companion animals and livestock. There are no FDA-labeled fenbendazole products for routine human clinical use.

Human parasitic infections are typically treated with agents that are specifically approved for human use. If you are evaluating options for a human infection, discuss FDA-vetted different substitutes with your clinician rather than using veterinary formulations.

Administration and dosing

Veterinary dosing regimen instructions differ by species, weight, formulation, and target parasite. For example, some canine recommendations in veterinary literature are in the range of 50 mg per kg once daily for three days for intestinal nematodes, but actual labeled doses vary by product.

There is no standard, approved fenbendazole dosing guideline for people in the US. Do not self-administer veterinary products. If considering an off-label or experimental approach, consult a licensed provider who can advise on safer, permitted diverse a side options.

For related measures for safety, see the effective the dynamic of social contacts require clear communication. caused by drugs section: drug-drug contact and response associated risks, and vigilant monitoring suggestions under safety, precautions, and metric monitoring.

Safety, health and safety measures, and vigilant monitoring

Caution is advised when fenbendazole exposure is repeated or prolonged, particularly in individuals with liver disease. Consider baseline and follow-up liver tests if use is prolonged and under clinical supervision.

• Assess liver function before prolonged therapy in at-risk patients or animals.
• Do not intermingle with other agents that significantly alter hepatic metabolism unless supervised by a clinician.
• Periodic clinical evaluation and laboratory metric monitoring may be warranted for extended or high-dose use.

Safety Warning messages and Warning messages and contraproof of

• Hypersensitivity to fenbendazole or any ingredient in the product.
• Severe, uncontrolled hepatic disease unless a clinician judges use necessary and health monitoring is arranged.
• Prenatal to lactation care: safety in human pregnancy is not established; avoid unless a clinician has performed a formal risk-benefit assessment.

Special rules apply for food animals (withdrawal intervals, records). Seek clarification from a professional a veterinarian for livestock guidance and food safety requirements.

Possible outcomes affecting wellbeing

Reported adverse health effects with fenbendazole are uncommon at labeled veterinary doses but can occur. Typical reactions noted in the literature include:

• Gastrointestinal signs such as reduced appetite, vomiting, or diarrhea.
• Transient hematologic changes in rare cases after high or prolonged exposures.
• Elevations in liver enzymes and occasional case reports suggestive of hepatic injury with benzimidazole agents.

If new or concerning symptoms appear after exposure, contact a healthcare provider or veterinarian promptly.

Clinical pharmacologic a mutual exchange of ideass create context for decisions. between drugs

Medications that affect hepatic function or clearance could change fenbendazole exposure and safety. Discuss concurrent drugs with a clinician.

• Agents that impair hepatic metabolism may increase fenbendazole levels and toxicity risk.
• There are case discussions in the literature about the study maps how social interactions evolve over time. with drugs such as methotrexate; specialist advice is recommended before combining.
• Experimental combinations with metabolic inhibitors or investigational agents should only occur in research settings or under specialist oversight.

See health monitoring recommendations under safety, risk mitigation measures, and watchful oversight.

Dose omission causing overdose deaths

If a dose is not received, give it as soon as you remember unless the next scheduled dose is near. Do not take two doses at the same time to compensate for a forgot to take the dose. In suspected the person overdosedcheck.k urgent medical or veterinary care and bring product information if available.

Large or repeated overdoses can lead to bone marrow suppression and low blood counts. Emergency evaluation may include blood tests and supportive care.

Proper storage management helps organize and track items. and handling in warehousing

• Store at room temperature, not exceeding 77 F (25 C).
• Keep containers closed, protect from moisture and direct sunlight.
• Do not freeze and keep out of reach of children and pets.

Different options and similar pharmaceuticals

For human parasitic infections, clinicians use FDA-approved drugs tailored to the species and site of infection. Common human-permitted optional options include:

• Albendazole - human benzimidazole used for many tissue and intestinal helminths.
• Mebendazole - indicated for several intestinal nematode infections in people.
• Ivermectin - available in human formulations for infections such as strongyloidiasis and onchocerciasis.
• The antihelminthic drug Praziquantel - the preferred agent for many trematode and cestode infections.
• Pyrantel pamoate - an over-the-counter option for pinworms and some roundworms in humans.
• Oxfendazole - related veterinary benzimidazole not approved for human use in the US.

Choice of drug depends on diagnosis, patient factors, and regulatory approval. To compare availability and costs, see conventional pricing details (USD).

Usual value range (USD)

Prices vary with retailer, formulation, quantity, and region. The figures below are approximate US cash prices intended as a general guide and may change:

• Fenbendazole (veterinary formulations): small single-dose packs or grams often range about 8 to 25 USD; larger multi-dose or bulk veterinary packages frequently list between 15 and 40 USD or higher depending on brand and size.
• Albendazole (human generic 200 mg): per-tablet prices can range widely, often from roughly 30 to 150 USD per tablet at retail without insurance, though coupons and pharmacy discounts may lower cost for a treatment course.
• Mebendazole (human): costs vary by formulation and availability; full-course transparent pricing for uninsured patients can reach into the low hundreds of USD in some cases.
• Ivermectin (human generic): many retail programs list generic tablets at roughly 3 to 10 USD per 3 mg tablet.
• Praziquantel medication (600 mg tablets, generic): typical per-tablet costs may be in the 5 to 20 USD range depending on supply source.
• Pyrantel pamoate (OTC human): often 8 to 20 USD per package depending on brand and size.

For current, precise pricing approach consult local pharmacies, online retailers, or official drug price databases. View the legal reference notes applicable to this. on permitted purchasing in the United States: legal and regulatory policy cautions.

Practical notes on United States law and regulation

• Fenbendazole is approved by the FDA for veterinary purposes only; there is no FDA approval for routine human therapeutic use of fenbendazole in the US.
• Advertising, labeling, or selling fenbendazole as a human treatment without FDA approval is not permitted.
• Prescribers typically will not prescribe veterinary fenbendazole for humans because labeled human dosing, safety data, and approved formulations are lacking.
• Importing unapproved drugs for human use is subject to FDA rules and is restricted except in limited circumstances where the agency exercises enforcement discretion. Using veterinary fenbendazole to treat people is not a recommended or approved pathway.
• When treating food-producing animals, additional regulations apply, including withdrawal intervals and recordkeeping. Consult USDA, FDA, and a veterinarian before administering pharmaceuticals to livestock.

For authoritative guidance consult the FDA website or speak with a licensed healthcare professional or veterinarian. Head to the the page's upper region quick a nutsell summary of the chapter.